A data model to predict <i>HER2</i> status in breast cancer based on the clinical and pathologic profiles of a large patient population at a single institution

作     者：Crowe, Joseph P. Patrick, Rebecca J. Rybicki, Lisa A. Escobar, Pedro F. Weng, David Budd, G. Thomas Tubbs, Raymond R. Procop, Gary W. Hicks, David G. 

作者机构：Cleveland Clin Fdn Breast Ctr Dept Gen Surg Cleveland OH 44195 USA Roswell Pk Canc Inst Dept Pathol & Lab Med Buffalo NY 14263 USA 

出 版 物：《BREAST》 (乳腺)

年 卷 期：2006年第15卷第6期

页      面：728-735页

核心收录：

学科分类：1002[医学-临床医学] 100201[医学-内科学(含：心血管病、血液病、呼吸系病、消化系病、内分泌与代谢病、肾病、风湿病、传染病)] 10[医学] 

主　　题：breast cancer HER2 data model survival trastuzumab FISH 

摘      要：Recently published clinical trial data have produced compelling evidence for increased survival when Herceptin is administered to patients whose tumors are HER2 amplified. Therefore, the accuracy of HER2 status is essential to determine which patients should or should not receive Herceptin. Although HER2 results obtained by FISH and IHC are often in agreement, there is a persistent group of cases in which results are discordant, particularly among tumors with intermediate results. A multivariable analysis was undertaken to determine relative significance of various clinical and pathologic findings for patients diagnosed with infiltrating ductal carcinoma, and a data model was produced that predicts which patients are most likely to have HER2 amplified tumors. Correlates of HER2 amplification were higher Scarff-Bloom-Richardson grade, younger age at diagnosis, and a comedo ductal carcinoma in situ component. (c) 2006 Elsevier Ltd. All rights reserved.